{"entity":{"type":"insider","cik":"0001821189","url":"/insider/0001821189","json_url":"/insider/0001821189.json","name":"Mainolfi Nello","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":72,"n_filings":21,"first":"2021-04-12","last":"2026-07-07","span_basis":"filed_date"},"name_variants":[{"name":"Mainolfi Nello","source":"filing","n_filings":21,"first_seen":"2021-04-12","last_seen":"2026-07-07"}],"transactions":[{"id":5963907,"accession":"0001193125-26-297817","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-297817","line_url":"/filing/0001193125-26-297817#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":119.0,"price_display":"119.00","price_state":"stated","total_value":5950000.0,"total_display":"5,950,000.00","total_whole":"5,950,000","shares_owned_after":666568.0,"shares_owned_after_display":"666,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-07","filed_date":"2026-07-07","scope":"insider"},{"id":5944381,"accession":"0001193125-26-295088","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-26-295088","line_url":"/filing/0001193125-26-295088","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":80000.0,"shares_display":"80,000","price_per_share":115.29409348875,"price_display":"115.29","price_state":"stated","total_value":9223527.4791,"total_display":"9,223,527.48","total_whole":"9,223,527","shares_owned_after":669904.0,"shares_owned_after_display":"669,904","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-02","scope":"insider","n_lines":5},{"id":5943955,"accession":"0001193125-26-192146","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-192146","line_url":"/filing/0001193125-26-192146","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":81.17924,"price_display":"81.18","price_state":"stated","total_value":2435377.2,"total_display":"2,435,377.20","total_whole":"2,435,377","shares_owned_after":679190.0,"shares_owned_after_display":"679,190","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-29","filed_date":"2026-04-29","scope":"insider","n_lines":3},{"id":6001273,"accession":"0001193125-26-072155","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-26-072155","line_url":"/filing/0001193125-26-072155","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":90.26041966666666,"price_display":"90.26","price_state":"stated","total_value":2707812.59,"total_display":"2,707,812.59","total_whole":"2,707,813","shares_owned_after":676431.0,"shares_owned_after_display":"676,431","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-25","filed_date":"2026-02-25","scope":"insider","n_lines":5},{"id":5143765,"accession":"0001193125-25-338415","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-25-338415","line_url":"/filing/0001193125-25-338415","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":78.06464502,"price_display":"78.06","price_state":"stated","total_value":2341939.3506,"total_display":"2,341,939.35","total_whole":"2,341,939","shares_owned_after":669091.0,"shares_owned_after_display":"669,091","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-31","filed_date":"2025-12-31","scope":"insider","n_lines":2},{"id":4702142,"accession":"0001193125-25-311504","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-311504","line_url":"/filing/0001193125-25-311504#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":89.17,"price_display":"89.17","price_state":"stated","total_value":8917000.0,"total_display":"8,917,000.00","total_whole":"8,917,000","shares_owned_after":660482.0,"shares_owned_after_display":"660,482","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-08","filed_date":"2025-12-08","scope":"insider"},{"id":4093250,"accession":"0001193125-25-256673","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-256673","line_url":"/filing/0001193125-25-256673","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":60.99123049333333,"price_display":"60.99","price_state":"stated","total_value":1829736.9148,"total_display":"1,829,736.91","total_whole":"1,829,737","shares_owned_after":664109.0,"shares_owned_after_display":"664,109","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-29","filed_date":"2025-10-29","scope":"insider","n_lines":3},{"id":4170966,"accession":"0001193125-25-204997","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-204997","line_url":"/filing/0001193125-25-204997#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":49.0,"price_display":"49.00","price_state":"stated","total_value":1470000.0,"total_display":"1,470,000.00","total_whole":"1,470,000","shares_owned_after":660482.0,"shares_owned_after_display":"660,482","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-16","filed_date":"2025-09-16","scope":"insider"},{"id":4100634,"accession":"0000950170-25-081199","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-081199","line_url":"/filing/0000950170-25-081199#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":49.0,"price_display":"49.00","price_state":"stated","total_value":1470000.0,"total_display":"1,470,000.00","total_whole":"1,470,000","shares_owned_after":660482.0,"shares_owned_after_display":"660,482","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-03","filed_date":"2025-06-03","scope":"insider"},{"id":6116712,"accession":"0000899243-22-001807","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0000899243-22-001807","line_url":"/filing/0000899243-22-001807","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8612.0,"shares_display":"8,612","price_per_share":52.08437015791918,"price_display":"52.08","price_state":"stated","total_value":448550.5958,"total_display":"448,550.60","total_whole":"448,551","shares_owned_after":474063.0,"shares_owned_after_display":"474,063","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-12","filed_date":"2022-01-12","scope":"insider","n_lines":4},{"id":6116696,"accession":"0000899243-22-001807","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-22-001807","line_url":"/filing/0000899243-22-001807","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16923.0,"shares_display":"16,923","price_per_share":53.99721211960054,"price_display":"54.00","price_state":"stated","total_value":913794.8207,"total_display":"913,794.82","total_whole":"913,795","shares_owned_after":479190.0,"shares_owned_after_display":"479,190","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-12","scope":"insider","n_lines":3},{"id":6116685,"accession":"0000899243-22-001807","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-001807","line_url":"/filing/0000899243-22-001807","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22465.0,"shares_display":"22,465","price_per_share":53.25603545070109,"price_display":"53.26","price_state":"stated","total_value":1196396.8364,"total_display":"1,196,396.84","total_whole":"1,196,397","shares_owned_after":476506.0,"shares_owned_after_display":"476,506","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-10","filed_date":"2022-01-12","scope":"insider","n_lines":4},{"id":4929950,"accession":"0000899243-21-039857","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0000899243-21-039857","line_url":"/filing/0000899243-21-039857","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6456.0,"shares_display":"6,456","price_per_share":53.68498401486989,"price_display":"53.68","price_state":"stated","total_value":346590.2568,"total_display":"346,590.26","total_whole":"346,590","shares_owned_after":464943.0,"shares_owned_after_display":"464,943","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-11","filed_date":"2021-10-12","scope":"insider","n_lines":2},{"id":4929941,"accession":"0000899243-21-039857","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899243-21-039857","line_url":"/filing/0000899243-21-039857","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41544.0,"shares_display":"41,544","price_per_share":56.75779950654727,"price_display":"56.76","price_state":"stated","total_value":2357946.0227,"total_display":"2,357,946.02","total_whole":"2,357,946","shares_owned_after":484507.0,"shares_owned_after_display":"484,507","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-08","filed_date":"2021-10-12","scope":"insider","n_lines":6},{"id":4426442,"accession":"0001209191-21-049922","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-049922","line_url":"/filing/0001209191-21-049922#line-4","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1037.0,"shares_display":"1,037","price_per_share":60.0317,"price_display":"60.03","price_state":"stated","total_value":62252.8729,"total_display":"62,252.87","total_whole":"62,253","shares_owned_after":452199.0,"shares_owned_after_display":"452,199","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-04","filed_date":"2021-08-05","scope":"insider"},{"id":4426436,"accession":"0001209191-21-049922","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-049922","line_url":"/filing/0001209191-21-049922#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5669.0,"shares_display":"5,669","price_per_share":60.0694,"price_display":"60.07","price_state":"stated","total_value":340533.4286,"total_display":"340,533.43","total_whole":"340,533","shares_owned_after":452199.0,"shares_owned_after_display":"452,199","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-03","filed_date":"2021-08-05","scope":"insider"},{"id":4669872,"accession":"0001209191-21-049110","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-21-049110","line_url":"/filing/0001209191-21-049110","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23456.0,"shares_display":"23,456","price_per_share":60.30029097885402,"price_display":"60.30","price_state":"stated","total_value":1414403.6252,"total_display":"1,414,403.63","total_whole":"1,414,404","shares_owned_after":454023.0,"shares_owned_after_display":"454,023","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-02","filed_date":"2021-08-02","scope":"insider","n_lines":3},{"id":4669854,"accession":"0001209191-21-049110","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-049110","line_url":"/filing/0001209191-21-049110#line-4","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6279.0,"shares_display":"6,279","price_per_share":60.068,"price_display":"60.07","price_state":"stated","total_value":377166.972,"total_display":"377,166.97","total_whole":"377,167","shares_owned_after":452199.0,"shares_owned_after_display":"452,199","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-30","filed_date":"2021-08-02","scope":"insider"},{"id":4669847,"accession":"0001209191-21-049110","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-049110","line_url":"/filing/0001209191-21-049110#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":680.0,"shares_display":"680","price_per_share":60.0,"price_display":"60.00","price_state":"stated","total_value":40800.0,"total_display":"40,800.00","total_whole":"40,800","shares_owned_after":452199.0,"shares_owned_after_display":"452,199","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-29","filed_date":"2021-08-02","scope":"insider"},{"id":4229247,"accession":"0001209191-21-048437","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-048437","line_url":"/filing/0001209191-21-048437#line-4","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3864.0,"shares_display":"3,864","price_per_share":60.1474,"price_display":"60.15","price_state":"stated","total_value":232409.5536,"total_display":"232,409.55","total_whole":"232,410","shares_owned_after":452199.0,"shares_owned_after_display":"452,199","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-28","filed_date":"2021-07-28","scope":"insider"},{"id":4229238,"accession":"0001209191-21-048437","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-048437","line_url":"/filing/0001209191-21-048437#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821189","owner_name":"Mainolfi Nello","owner_display_name":"Mainolfi Nello","owner_url":"/insider/0001821189","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9015.0,"shares_display":"9,015","price_per_share":60.1483,"price_display":"60.15","price_state":"stated","total_value":542236.9245,"total_display":"542,236.92","total_whole":"542,237","shares_owned_after":452199.0,"shares_owned_after_display":"452,199","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-26","filed_date":"2021-07-28","scope":"insider"}],"collapsed":true,"next_cursor":"2021-07-26|4229238","ledger_fault":false,"count":{"value":72,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":72,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":72},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Director, Officer (Chief Executive Officer)","n_filings":21,"first_seen":"2021-04-12","last_seen":"2026-07-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001821189","retrieved_at":"2026-08-22T09:37:49+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}